Drug Profile
Research programme: ubiquitin ligases - Merck/Rigel
Alternative Names: Ubiquitin ligases research programme - Merck/RigelLatest Information Update: 29 Mar 2010
Price :
$50
*
At a glance
- Originator Merck & Co; Rigel Pharmaceuticals
- Class Ligases
- Mechanism of Action Ubiquitin-protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Immunological disorders; Viral infections
Most Recent Events
- 19 May 2006 This programme is still in active development
- 18 Nov 2004 Preclinical trials in Immunological disorders in USA (unspecified route)
- 18 Nov 2004 Preclinical trials in Viral infections in USA (unspecified route)